About Xiamen Amoytop Biotech Company

The company is an innovative biomedical enterprise and a science and technology innovation board listed company mainly engaged in R&D, production and sales of recombinant proteins and long-term modifying drugs. The company takes immune-related cytokine drugs as its main research direction, and is committed to becoming a leader in cytokine drug-based systemic immunity solutions to provide better solutions for the treatment of major diseases such as viral hepatitis and malignant tumors. The company is an innovative biomedical enterprise mainly engaged in R&D, production and sales of recombinant proteins and long-term modified drugs. The company currently has five products on the market, namely Pegbin, Peggen, Terli, Terzine, and Telcon. Corporate honors: 2023 Top 100 Pharmaceutical Innovative Enterprises, China's Top 100 Listed Companies Growing, Fujian Top 100 Innovative Private Enterprises, China's Silver Diamond Award for Liver Disease Diagnosis and Treatment Technology, National Innovative Enterprise, Fujian Strategic Emerging Industry Key Enterprise, National Torch Program Key High-tech Enterprise, Postdoctoral Research Workstation, and the first prize of the 2023 Xiamen Science and Technology Progress Award.